We are building the bridge between complex molecular data and everyday clinical decisions
Premium CBD+THC-infused gummies target stress relief, relaxation, and sleep recovery
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The safety profile was described as manageable, though not without notable toxicities
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
